HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kremer, J. M Search for Related Content PubMed PubMed Citation Articles by Kremer, J. M Agricola Articles by Kremer, J. M

n-3 Fatty acid supplements in rheumatoid arthritis^1,2

¹ From the Division of Rheumatology, Albany Medical College, New York.

² Address reprint requests to JM Kremer, Division of Rheumatology, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208.

	ABSTRACT

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 
Ingestion of dietary supplements of n-3 fatty acids has been consistently shown to reduce both the number of tender joints on physical examination and the amount of morning stiffness in patients with rheumatoid arthritis. In these cases, supplements were consumed daily in addition to background medications and the clinical benefits of the n-3 fatty acids were not apparent until they were consumed for 12 wk. It appears that a minimum daily dose of 3 g eicosapentaenoic and docosahexaenoic acids is necessary to derive the expected benefits. These doses of n-3 fatty acids are associated with significant reductions in the release of leukotriene B₄ from stimulated neutrophils and of interleukin 1 from monocytes. Both of these mediators of inflammation are thought to contribute to the inflammatory events that occur in the rheumatoid arthritis disease process. Several investigators have reported that rheumatoid arthritis patients consuming n-3 dietary supplements were able to lower or discontinue their background doses of nonsteroidal antiinflammatory drugs or disease-modifying antirheumatic drugs. Because the methods used to determine whether patients taking n-3 supplements can discontinue taking these agents are variable, confirmatory and definitive studies are needed to settle this issue. n-3 Fatty acids have virtually no reported serious toxicity in the dose range used in rheumatoid arthritis and are generally very well tolerated.

Key Words: n-3 Fatty acids • rheumatoid arthritis • fish oil • inflammation • eicosapentaenoic acid • docosahexaenoic acid

	INTRODUCTION

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 
Our appreciation of the possible role of nutritional manipulation in the treatment of inflammatory disease has increased along with our understanding of immunity, eicosanoid metabolism, and cellular biology. Although it has been known for some time that disease processes can interfere with adequate nutrition, we are only now beginning to understand how altered nutritional status may contribute to or alter the pathogenesis of disease. These principles represent an evolution of thinking from the relatively recent past, when contributors to the field of inflammation believed it extremely unlikely that dietary manipulation could affect patients in any way.

n-3 Fatty acids are given as dietary supplements to patients who have rheumatoid arthritis, the most common systemic inflammatory rheumatic disease. These supplements are consumed while patients continue to take their background medications, such as slow-acting, antirheumatic drugs and nonsteroidal antiinflammatory drugs (NSAIDs). Most studies of n-3 fatty acid supplementation use fatty acids in the triacylglycerol form, although ethyl esters of fatty acids have also been studied. Although there are some conflicting data on the absorption of the ethyl ester compared with the triacylglycerol (1, 2), most investigators believe that there is little practical difference in tolerability or efficacy between these 2 formulations. Some investigators advocate use of a free fatty acid formulation (in which there is no linkage to a glycerol or an ester), although, to date, no studies in humans with rheumatoid arthritis have used this formulation.

	ANIMAL STUDIES

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 
Certain inbred strains of mice develop spontaneous autoimmune disease and have been used as models to study the effects of dietary intervention. NZB x NZW F1 MRL 1pr and B x SB/Mjp strains all develop diffuse glomerulonephritis as well as serologic and clinical features akin to human systemic lupus erythematosus. In trials reported >10 y ago, dietary supplementation with marine lipids significantly ameliorated disease activity in these animals (3, 4). Not all animal studies of dietary supplementation with n-3 fatty acids have resulted in beneficial effects: type II collagen–induced arthritis worsened in animals fed fish oil compared with those fed beef tallow (5). Interestingly, recent studies of purified eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3) indicate that the mixture of these 2 major n-3 fatty acid constituents of fish oil may be more effective than either fatty acid by itself (6).

	HUMAN STUDIES

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 
Several investigators have studied the effects of dietary fish-oil supplements in patients with rheumatoid arthritis. Studies of predominantly white subjects of northern European background have been reported from the United States (7–11), Australia (12), and Europe (13–19). It is unlikely that background dietary habits were uniform in these populations, however. Some populations were known to consume more fish oil in their diet (16) than others (20). The benefit most often observed with fish-oil supplementation is an improvement in the number of tender joints on physical examination (8, 10–15), although some authors reported improvement in the Ritchie Articular Index (15, 18) and in morning stiffness (10, 12, 15). n-3 Fatty acid supplements have been studied in comparison with a variety of dietary interventions, including inert paraffin wax (7), corn oil (11, 15), olive oil (8–10), and a specially prepared mixture of fatty acids designed to reproduce local dietary intake (16–18). Improvements in the number of tender joints and in morning stiffness were confirmed in a meta-analysis of published studies that used a wide range of daily dietary supplementation with n-3 fatty acids (21).

It is accurate to portray the overall clinical response to fish-oil supplements in these investigations as modest (22, 23). However, it is clear that dietary fatty acids effect reproducible alterations in eicosanoid metabolism that should aid in the amelioration of inflammation (8, 9, 12, 24–26). In addition, fish-oil supplements are associated with decreased production of interleukin 1ß in healthy humans (27) and in patients with rheumatoid arthritis (8, 10). It is the unique ability of dietary fatty acids to alter the fatty acid constituents of cell membranes (22) that has generated interest in the potential of the highly polyunsaturated fatty acids to influence an array of immune variables.

We were interested in expanding our observations of the beneficial effects of fish oil in patients with rheumatoid arthritis to determine whether patients consuming high-dose supplements would be better able to discontinue use of NSAIDs than would a control population given corn oil (11). Forty-nine patients taking the NSAID diclofenac were studied in a prospective, double-blind investigation. Patients randomly assigned to receive fish oil ingested 130 mg n-3 fatty acids•kg^-1•d^-1 (ethyl ester concentrate prepared by the National Institutes of Health, Bethesda, MD) while control patients consumed corn oil capsules. After 18–22 wk, all patients were given placebo diclofenac but continued their respective fatty acid supplements for another 8 wk, at which time all patients were given corn oil. Clinical evaluations were performed for several months after diclofenac treatment was discontinued and also after the fish-oil supplements were stopped. Several cytokines were measured throughout the study, including interleukins 1, 2, 6, and 8 and tumor necrosis factor .

We found a significant reduction in the number of tender joints and improvements in other clinical variables of disease over 18–22 wk from baseline in the patients who consumed dietary supplements of fish oil while taking diclofenac (11). However, none of the improvements in the patients receiving fish oil were significantly different at the time of the maximum duration of diclofenac therapy (at 18 or 22 wk) from the improvements in patients receiving corn oil. Patients receiving corn oil tended to have fewer swollen joints during this time interval than at baseline. In addition, the magnitude of the improvement from baseline observed in patients receiving high doses of fish oil was indistinguishable from that reported previously when patients consumed total n-3 fatty acid dosages of 3–6 g/d (8, 10). We cannot, therefore, recommend further investigations with the dosages we used, which resulted in the ingestion of 9 g n-3 fatty acids/d by a 70-kg person, because it appears that dietary supplements containing 3–6 g n-3 fatty acids are sufficient.

Improvements from baseline in rheumatoid arthritis patients consuming fish oil are often not significantly different from improvements in patients receiving other dietary fatty acid interventions. This may be either because the biological effects are not powerful enough or because of a placebo effect—real biological effects induced by the so-called placebo fatty acids. We previously wrestled with the issue of an ideal control fatty acid to compare with fish oil (10) and chose corn oil in our most recent investigation (11) after using olive oil (8, 10). It is possible that any mono- or polyunsaturated fatty acid has significant potential immune effects. We believe that the issue of the ideal placebo dietary intervention to compare with fish oil in the study of autoimmune inflammatory disease has not yet been settled.

We examined the clinical status of patients after they had stopped receiving diclofenac but continued to receive fish oil or corn oil in several ways (11). We examined clinical status after the discontinuation of diclofenac and the maximal duration of fish-oil exposure (week 26 or 30) and compared this with baseline status while patients were receiving diclofenac. The improvement in the number of tender joints was significant in the patients continuing to receive fish-oil treatment compared with both baseline status and with patients receiving corn oil during the same period. We observed a significant decrease in interleukin 1, confirming our previous observations (8, 10), but did not find significant decreases in interleukins 2, 6, or 8 or tumor necrosis factor .

Others have investigated whether dietary fish-oil supplements can affect NSAID requirements in patients with rheumatoid arthritis. Skoldskam et al (14) used open, patient-directed reduction of NSAID use and found that patients consuming fish oil could significantly reduce their NSAID dose compared with a control group. In this study, patients lowered or discontinued their use of NSAIDs in an open manner although they were blinded to the dietary supplement consumed. Belch et al (17) used open, physician-directed reduction of NSAID use while subjects consumed 240 mg EPA and 450 mg -linolenic acid daily and found that, after 1 y, NSAID doses could be reduced significantly (17). In another study, Kjeldsen-Kragh et al (15) substituted placebo naproxen for the real drug in a stepwise manner. In this open study, the investigators were aware that 2 of 3 treatment groups would be discontinuing naproxen treatment. Nevertheless, they reported that patients receiving fish oil tolerated discontinuation of the NSAID better than did patients receiving corn oil. Finally, Lau et al (28) reported that patients receiving fish oil could significantly reduce their NSAID dose compared with that of a control group. We believe our data (11) support these observations that selected individuals with rheumatoid arthritis can discontinue or reduce NSAID therapy while consuming n-3 fatty acid supplements.

	OTHER INFLAMMATORY CONDITIONS

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 
Subsequent to the reports of the benefits of fish-oil supplementation in patients with rheumatoid arthritis, n-3 fatty acid supplements have been used with some reported benefit in patients with inflammatory bowel disease (29) and immunoglobulin A nephropathy (30). Many other inflammatory conditions may benefit from the n-3 fatty acid–induced changes in eicosanoid metabolism and decreased production of interleukin 1 described above.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 
On the basis of the totality of the data, it is recommended that patients consume dietary supplements containing 3–6 g n-3 fatty acids daily for 12 wk. The dietary supplement should not replace the standard therapeutic medical regimen, but be added to it. Note, however, that there are many forms of arthritis and that clinical studies demonstrating efficacy have been performed only in patients with rheumatoid arthritis. After taking n-3 fatty acid dietary supplements for 3–4 mo, patients may try reducing their NSAID dose under the supervision of a physician.

	REFERENCES

TOP ABSTRACT INTRODUCTION ANIMAL STUDIES HUMAN STUDIES OTHER INFLAMMATORY CONDITIONS CONCLUSIONS REFERENCES

 

1. Beckermann B, Beneke M, Seitz I. Comparison of bioavailability of EPA and DHA from triglycerides, free fatty acids and ethyl ester after single oral administration to 8 female volunteers. Biochemische Eutwicklung 1988;S1:298–30.
2. Luley C, Wieland H, Grunwald J. Bioavailability of omega-3 fatty aids: ethylester preparations are as suitable as triglyceride preparations. Aktuelle Eruahr Med 1990;15:123–35.
3. Prickett JD, Robinson DR, Steinberg AD. Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW f1 mice. J Clin Invest 1981;68:556–9.
4. Robinson DR, Prickett JD, Makoul GT, Steinberg AD, Colvin RB. Dietary fish oil reduces progression of established renal disease in (NZB x NZW) F1 mice and delays renal disease in BXDB and MRL/1 strains. Arthritis Rheum 1986;29:539–46.[Medline]
5. Prickett JD, Trentham DE, Robinson DR. Dietary fish oil augments the induction of arthritis in rats immunized with type II collagen. J Immunol 1984;132:725–9.[Abstract]
6. Robinson DR, Tateno S, Knoell C, et al. Dietary marine lipids suppress murine autoimmune disease. J Intern Med 1989;225(suppl):211–6.
7. Kremer JM, Biguouette J, Michalek AU. Effects of manipulating dietary fatty acids on clinical manifestations of rheumatoid arthritis. Lancet 1985;1:184–7.[Medline]
8. Kremer JM, Jubiz W, Michalek A, et al. Fish oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled crossover study. Ann Intern Med 1987;106:497–503.
9. Sperling RI, Weinblatt M, Robin JL, et al. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum 1987;30:988–97.[Medline]
10. Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:810–20.[Medline]
11. Kremer JM, Lawrence DA, Petrillo GF, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs: clinical and immune correlates. Arthritis Rheum 1995;38:1107–14.[Medline]
12. Cleland LG, French JK, Betts WH, Murphy GA, Elliott MJ. Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol 1988;15:1471–5.[Medline]
13. Van Der Temple H, Tulleken JF, Limburg PC, Muskiet FAJ, van Riiswijk MH. Defects of fish oil supplementation in rheumatoid arthritis. Ann Rheum Dis 1990;49:76–80.[Abstract/Free Full Text]
14. Skoldstam L, Borjesson O, Kjllman A, Seiving B, Akesson B. Effect of six months of fish oil supplementation in stable rheumatoid arthritis: a double blind, controlled study. Scand J Rheumatol 1992;21:178–85.[Medline]
15. Kjeldsen-Kragh J, Lund JA, Riise T, et al. Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis. J Rheumatol 1992;19:1531–6.[Medline]
16. Nielsen GI, Faarvang KL, Thomsen BS, et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: a randomized, double blind trial. Eur J Clin Invest 1992;22:687–91.[Medline]
17. Belch JJF, Ansell D, Madhok R, Dowd AO, Sturock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis 1988;47:96–104.[Abstract/Free Full Text]
18. Sperson GT, Grunne N, Lervang HH, et al. Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids. Clin Rheumatol 1992;11:393–5.[Medline]
19. Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of n-3 fatty acid supplementation in active rheumatoid arthritis: a 12 month double blind controlled study. Arthritis Rheum 1994;37:824–9.[Medline]
20. Bigaouette J, Timchalk MA, Kremer JM. Nutritional adequacy of diet and supplements in patients with rheumatoid arthritis taking medication. J Am Diet Assoc 1987;87:11–2.
21. Fortin PR, Liang MH, Beckett LA, et al. A meta-analysis of the efficacy of fish oil in rheumatoid arthritis. Arthritis Rheum 1992;35:S201 (abstr).
22. Kremer JM. Clinical studies of n-3 fatty acid supplementation in patients with rheumatoid arthritis. Rheum Dis Clin North Am 1992;17:391–402.
23. Kremer JM. Nutrition in the rheumatic disease. In: Textbook of rheumatology. 5th ed. Philadelphia: WB Saunders, 1997:521–33.
24. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on the in vitro neutrophil and monocyte leukotrienic generation and neutrophil function. N Engl J Med 1985;312:1217–24.[Abstract]
25. Robinson DR, Tateno S, Balkrishna P, Hirai A. Lipid mediators of inflammatory and immune reactions. JPEN J Parenter Enteral Nutr 1988;12:375–425.
26. Lewis RA, Austin KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645–55.[Medline]
27. Endres S, Ghorbani R, Kelley VE, et al. The effects of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265–71.[Abstract]
28. Lau CS, Morely KD, Belch JJ. Effects of fish oil supplementation on the non-steroidal anti-inflammatory drug requirements in patients with mild rheumatoid arthritis: a double blind placebo controlled study. Br J Rheumatol 1993;32:982–9.[Abstract/Free Full Text]
29. Stenson WF, Eirt D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992;116:609–14.
30. Donadio JV, Bergstrath EJ, Offord KP, Spenser DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994;331:1194–9.[Abstract/Free Full Text]

This article has been cited by other articles:

				C. von Schacky and W. S. Harris Cardiovascular benefits of omega-3 fatty acids Cardiovasc Res, January 15, 2007; 73(2): 310 - 315. [Abstract] [Full Text] [PDF]

				Y. Freund-Levi, M. Eriksdotter-Jonhagen, T. Cederholm, H. Basun, G. Faxen-Irving, A. Garlind, I. Vedin, B. Vessby, L.-O. Wahlund, and J. Palmblad {omega}-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial. Arch Neurol, October 1, 2006; 63(10): 1402 - 1408. [Abstract] [Full Text] [PDF]

				P. C Calder n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases Am. J. Clinical Nutrition, June 1, 2006; 83(6): S1505 - 1519S. [Abstract] [Full Text] [PDF]

				M. Senkal, R. Haaker, J. Linseisen, G. Wolfram, H.-H. Homann, and P. Stehle Preoperative Oral Supplementation with Long-Chain {Omega}-3 Fatty Acids Beneficially Alters Phospholipid Fatty Acid Patterns in Liver, Gut Mucosa, and Tumor Tissue JPEN J Parenter Enteral Nutr, July 1, 2005; 29(4): 236 - 240. [Abstract] [Full Text] [PDF]

				A. Bhattacharya, M. Rahman, J. Banu, R. A. Lawrence, H. S. McGuff, I.R. Garrett, M. Fischbach, and G. Fernandes Inhibition of Osteoporosis in Autoimmune Disease Prone MRL/Mpj-Faslpr Mice by N-3 Fatty Acids J. Am. Coll. Nutr., June 1, 2005; 24(3): 200 - 209. [Abstract] [Full Text] [PDF]

				R. Oh Practical Applications of Fish Oil ({Omega}-3 Fatty Acids) in Primary Care J Am Board Fam Med, January 1, 2005; 18(1): 28 - 36. [Abstract] [Full Text] [PDF]

				Y.-Y. Fan, L. H. Ly, R. Barhoumi, D. N. McMurray, and R. S. Chapkin Dietary Docosahexaenoic Acid Suppresses T Cell Protein Kinase C{theta} Lipid Raft Recruitment and IL-2 Production J. Immunol., November 15, 2004; 173(10): 6151 - 6160. [Abstract] [Full Text] [PDF]

				Y.-Y. Fan, D. N. McMurray, L. H. Ly, and R. S. Chapkin Dietary (n-3) Polyunsaturated Fatty Acids Remodel Mouse T-Cell Lipid Rafts J. Nutr., June 1, 2003; 133(6): 1913 - 1920. [Abstract] [Full Text] [PDF]

				R. Irons, M. J. Anderson, M. Zhang, and K. L. Fritsche Dietary Fish Oil Impairs Primary Host Resistance Against Listeria monocytogenes More than the Immunological Memory Response J. Nutr., April 1, 2003; 133(4): 1163 - 1169. [Abstract] [Full Text] [PDF]

				S. N. Cheuvront The Zone Diet Phenomenon: A Closer Look at the Science behind the Claims J. Am. Coll. Nutr., February 1, 2003; 22(1): 9 - 17. [Abstract] [Full Text] [PDF]

				K. C. Switzer, D. N. McMurray, J. S. Morris, and R. S. Chapkin (n-3) Polyunsaturated Fatty Acids Promote Activation-Induced Cell Death in Murine T Lymphocytes J. Nutr., February 1, 2003; 133(2): 496 - 503. [Abstract] [Full Text] [PDF]

				M. A. de Pablo, M. A. Puertollano, and G. Alvarez de Cienfuegos Biological and Clinical Significance of Lipids as Modulators of Immune System Functions Clin. Vaccine Immunol., September 1, 2002; 9(5): 945 - 950. [Full Text] [PDF]

				Z. B. Kang, Y. Ge, Z. Chen, J. Cluette-Brown, M. Laposata, A. Leaf, and J. X. Kang Adenoviral gene transfer of Caenorhabditis elegansn-3 fatty acid desaturase optimizes fatty acid composition in mammalian cells PNAS, March 16, 2001; (2001) 61040198. [Abstract] [Full Text]

				V. Rozenfeld, L. Chagan, and E. Kleyman The Year in Review: Rheumatology Journal of Pharmacy Practice, February 1, 2001; 14(1): 54 - 69. [Abstract] [PDF]

				M. J James, R. A Gibson, and L. G Cleland Dietary polyunsaturated fatty acids and inflammatory mediator production1 Am. J. Clinical Nutrition, January 1, 2000; 71(1): 343S - 348S. [Abstract] [Full Text] [PDF]

				J. J. Belch and A. Hill Evening primrose oil and borage oil in rheumatologic conditions1 Am. J. Clinical Nutrition, January 1, 2000; 71(1): 352S - 356S. [Abstract] [Full Text] [PDF]

				Z. B. Kang, Y. Ge, Z. Chen, J. Cluette-Brown, M. Laposata, A. Leaf, and J. X. Kang Adenoviral gene transfer of Caenorhabditis elegansn-3 fatty acid desaturase optimizes fatty acid composition in mammalian cells PNAS, March 27, 2001; 98(7): 4050 - 4054. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kremer, J. M Search for Related Content PubMed PubMed Citation Articles by Kremer, J. M Agricola Articles by Kremer, J. M